anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective observational study of usual care of patients undergoing treatment for schizophrenia or bipolar I disorder at CBHOs. Up to 50 CBHOs will be selected as sites for this study. Treating clinicians at these sites will notify the designated research coordinators for this study when they are initiating a patient on a new antipsychotic medication (including risperidone long acting injectable or paliperidone palmitate) or if they are treating a patient with risperidone long acting injectable or paliperidone palmitate. New initiation will include patients not previously on any antipsychotic medication as well as those switched from one antipsychotic to another. Switches may include but are not limited to switches among different types of oral antipsychotics, from an oral antipsychotic to Long Acting Therapy (LAT), or from LAT to an oral antipsychotic. Site research staff will screen potential participants identified by the clinicians and enroll those meeting study criteria who consent to study participation. Sites will maintain a screening log of all potential participants. The target enrollment for this study is up to 2,450 participants. Enrollment by cohort will be monitored and sites will be notified to stop enrollment if target enrollment for a particular cohort has been reached. Eligible participants who consent to the study will be recruited into one of two samples: participants with a schizophrenia diagnosis (target n=2,250) and participants with a bipolar I disorder diagnosis (target n=200). There will be four cohorts: risperidone long acting injectable new starts (target n=475); risperidone long acting injectable continuous users (target n=75); paliperidone palmitate new starts or continuous users (target n=1,200); and other antipsychotic new starts (target n=700). During the entire study follow-up period participants will receive their medication per usual care in their treatment setting and no study drug will be provided. Enrolled participants will be followed prospectively over a 12-month study period, with interviews at baseline, 6 and 12 months. Sites will also abstract medical history and healthcare utilization information from the chart of each enrolled participant. There will be three chart abstractions (baseline, 6 Months, 12 Months). The baseline abstraction will cover services rendered in the 6 months prior to antipsychotic initiation or switch, or from their first visit to the CBHO if the individual did not receive services for as long as 6 months prior to initiation or switch. The 6M and 12M abstractions will each cover services rendered in the prior 6 months. When all three abstractions are complete, the data will cover the period from 6 months before baseline to 12 months after baseline. If a Serious Adverse Event (SAE) associated with a J\&J medicinal product occurs the investigator will record it in the source document as well as fax the SAE form to J\&J internal safety group within 24 hours. Treatment as usual
Participants will be given the probiotic supplement VSL#3, a commercially available product. VSL#3 is taken by mouth, either once or twice daily, and is dispensed in sachets, each containing 450 billion colony forming units of bacterial strains. Participants will undergo a screening visit. They will be asked to provide a stool sample by the next visit. Within 3 weeks they will return with a stool sample and receive the VSL#3 sachets as well as another stool collection kit. After 6 weeks of taking VSL#3, they will return for their final visit, with their stool sample. Blood will be drawn at the second and third visits.
The present invention relates to a medicine for treating hemorrhoids and fistula. The medicine of the present invention is made of 25 to 35 portions of pagodatree flower bud, 25 to 35 portions of rhizome coptidis from Sichuan of China, 10 to 25 portions of pangolin, 10 to 25 portions of concha hallotidis, 8 to 18 portions of bombyx batryticatus, 10 to 25 portions of garden burnet root and 88 to 163 portions of honey. The medicine of the present invention has the functions of clearing heat, cooling blood, expelling toxin, eliminating swelling, stimulating the blood circulation to remove stasis, softening hard masses, removing blood stasis, eliminating the hemorrhoids, promoting the blood circulation for expelling wind, stopping bleeding and alleviating pain. When used for treating internal hemorrhoids, external hemorrhoids and mixed hemorrhoids, the present invention treating both manifestation and root cause. The medicine of the present invention has the advantages of conspicuous curative effect, rapid and persistent action, easy administration and no toxic side effect, and is optimum medicine for treating the hemorrhoids. Through clinical application for many years, continuous improvement, shortage elimination, quintessence reservation and clinical verification, the present invention has the advantages of unique effects, high curative ratio (which reaches 100%) and no recurrence.
Compositions containing a nucleic acid nanostructure having a desired geometric shape and antigens bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle or icosahedron. The nanostructure design allows for control of the relative position and/or stoichiometry of the antigen bound to its surface. The antigens displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be an HIV immunogen such as eOD-GT6, eOD-GT8, or variants thereof. The compositions may thus be useful as immunogens, vaccines, immunostimulators, adjuvants, and the like. Methods of inducing immune responses, inducing protective immunity, inducing the production of neutralizing antibodies or inhibitory antibodies, inducing tolerance, and treating cancer, infectious or autoimmune diseases are also provided.
FIELD: dermatology. SUBSTANCE: composition may be used in cosmetology and dermatology against dandruff, and also as an antimycotic agent. Cosmetic or dermatological composition for treatment of skin inflammatory diseases contains in physiologically acceptable media at least one alkynylcarbamate of definite formula and at least one polyol separated from a group consisting of unesterified polyols, simple esters of polyol and simple glycosil esters of polyol. Said polyols are saturated or unsaturated, linear, branched or cyclic, containing or without heteroatom, containing or without additional chemical functions, separated from carbonyl and carboxyl functions. Method of cosmetic removal of dandruff from hair is carried out by application of composition on hair with the following washing. EFFECT: higher antimycotic activity, solubility and stability in media. 17 cl
Suturing is one of the most common procedure in the emergency department, however, it often provokes anxiety and pain. 1-2 Failure to manage patients' anxiety and pain during wound closure can cause difficulties for health care providers to complete the procedures and reduce the success rates. 3 Experience of anxiety and pain may also increase the need for medication, reduce patients' satisfaction rate and cause negative physiological parameters such as increased blood pressure and heart rate. 4-5.

Traditionally, nonpharmacological intervention such as listening to music, chatting, and guided imagery is applied to reduce patient's anxiety and pain. However these measures fail to provide patients with significant distraction because patients would inevitably see the procedure that causes considerable distress during the procedure. Thus, the development of further strategies to provide a significant distraction to alleviate patients' anxiety and pain during suturing is warranted.

With advanced technologies, virtual reality (VR) provides significant distraction. Clinical trials indicate that use of VR achieved a statistically significant decrease in anxiety and pain in different operations such as hand 6, lipoma incision 7, Gynecology 8, and debridement 9. However, only a handful of studies conducted among adult patient with ambulatory laceration repairing examined the effectiveness of VR in anxiety and pain. To the best of our knowledge, no study specifically focus on the effects of VR on anxiety and pain in Chinese adult patients undergoing an awake suture in emergency room in Hong Kong. Eighty participants will be assigned to the experimental group or to the control group by randomization.

After written informed consent will be obtained from patients, the baseline data (T0) will be obtained from the participants including sociodemographic, anxiety, blood pressure, and pulse rate. Subsequently, randomization is conducted. Throughout the procedure (T1), the additional medication requirements and physiological parameters will be recorded. The anxiety, pain and satisfaction and physiological parameters will also be recorded after the procedure. Data will be analyzed using IBM SPSS 23.0. Descriptive statistics, including frequency, percentage, mean and standard deviation will be used to describe the data. Chi-square tests compare categorical variables, and independent t-tests compare continuous variables. Generalized Estimation Equation will be used to examine the effectiveness of the VR intervention versus the control group will be evaluated by comparing the study outcomes. Two-tailed tests will be used with a significant level of 0.05.
Over the course of the study, participants within this group will receive 12 sessions of Low-Level Laser Therapy (LLLT) treatment over a duration of 4 weeks using the Richmar TheraTouch LX2 device. Treatment location will be determined through assessment of each qualifying participant. Treatment sessions will be limited to a single area of the body associated with the qualifying participant's primary pain complaint.
The invention discloses a traditional Chinese medicine vertebral cataplasm substrate and a preparation method thereof. The vertebral cataplasm substrate is composed of: an adhesion agent, a thickening agent, a humectant, a shape fixing agent, a crosslinking agent, and a penetration enhancer. The vertebral cataplasm substrate is water-soluble, and causes no pollution harm to the environment and to human bodies. The cataplasm substrate is easy to wash, and causes no allergic reaction. A drug load is high, and drug effect duration is long. When traditional Chinese medicine extract or powder with rheumatic arthralgia resisting activity is added into the vertebral cataplasm substrate, a prepared cataplasm can be adhered to a position such as a human spine for more than 24h with no auxiliary adhesion material. Therefore, the adhesion of existing cataplasm in market is substantially improved. The obtained cataplasm has the advantages of good body followability, comfortable sticking, no irritation to skins, and no allergic reaction. The property of the vertebral cataplasm substrate is stable. The vertebral cataplasm substrate is used for preparing a cataplasm comprising traditional Chinese medicine, and is a transdermal administration substrate with good adhesion property.
Both groups were prescribed the same type of exercise, duration of exercise and number of repetitions. group 1 completed the exercise program and marked the exercise attendance schedule. At the end of the program, these charts were collected from the subjects and the continuity was evaluated. The group marked the exercises completed with 2 phone app. In the program used, exercise continuity of the cases was evaluated as days.

Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
This study aimed to compare the efficacy of autologous blood (AB) and corticosteroid (CS) injections and their combination in treating lateral epicondylitis (LE), hypothesizing that the combined approach might offer immediate symptom resolution and lower recurrence. Methods: A total of 120 patients diagnosed with lateral epicondylitis were systematically distributed among three distinct therapeutic injection groups. Those in the AB group were administered 1ml of autologous venous blood mixed with 2ml of 2% prilocaine HCl. Participants in the CS category were given 1ml of 40 mg methylprednisolone acetate mixed with 2ml of 2% prilocaine HCl. Meanwhile, patients in the combined group received a mixture containing 1ml each of autologous venous blood and 40mg methylprednisolone acetate, along with 1ml of 2% prilocaine HCl. Prior to receiving their respective injections, a comprehensive assessment of all participants was carried out. Follow-up assessments were subsequently conducted on days 15, 30, and 90, utilizing metrics of patient-rated tennis elbow evaluation (PRTEE) and measurements of hand grip strength (HGS).
This invention is a novel method for detecting and localizing specific nucleic acid sequences in a sample with a high degree of sensitivity and specificity. The method and novel compositions used in the method involve the use of Probe Nucleic Acids, the production of nucleic acid binding regions and the use of nucleic acid Target Binding Assemblies to detect and localize specific Target Nucleic Acids. The detection and localization of the Target Nucleic Acid is accomplished even in the presence of nucleic acids which have similar sequences. The method provides for a high degree of amplification of the signal produced by each specific binding event. In particular, methods and compositions are presented for the detection of HIV and HPV nucleic acid in samples. These methods and compositions find use in diagnosis of disease, genetic monitoring, forensics, and analysis of nucleic acid mixtures. Some of the novel compositions used in the detection method are useful in preventing or treating pathogenic conditions.
Belonging to the technical field of health food, the invention discloses a Nostoc flagelliforme peony seed health care composition, a capsule and a preparation method thereof. The health care composition consists of the following components by mass: 1 part of Nostoc flagelliforme, and 80-90 parts of peony seeds. The capsule is prepared from the Nostoc flagelliforme peony seed health care composition, mannitol, starch and talcum powder. Nostoc flagelliforme has the effects of lowering pressure and regulating nerve, etc., can be used for treating rickets, dysentery, high blood pressure, trachitis, epistaxis, malnutrition and other diseases. Peony seeds are rich in alpha-linolenic acid, and alpha-linolenic acid can improve the organism immunity, improve intelligence, protect eyesight, reduce blood glucose, blood pressure and blood lipid, prevent and improve thrombotic diseases, and inhibit cancer incidence and metastasis. Combined use of Nostoc flagelliforme and peony seeds can enhance the nutrition and health care efficacy, enhance the body function and strengthen immunity.
BACKGROUND: Ovarian carcinoma (OC) is a prevalent gynecological malignancy associated with high recurrence rates and mortality, often diagnosed at advanced stages. Despite advances in immunotherapy, immune exhaustion remains a significant challenge in achieving optimal tumor control. However, the exploration of intratumoral heterogeneity of malignant epithelial cells and the ovarian cancer tumor microenvironment is still limited, hindering our comprehensive understanding of the disease.
MATERIALS AND METHODS: Utilizing single-cell RNA sequencing (scRNA-seq), we comprehensively investigated the cellular composition across six ovarian cancer patients with omental metastasis. Our focus centered on analysis of the malignant epithelial cells. Employing CytoTRACE and slingshot pseudotime analyses, we identified critical subpopulations and explored associated transcription factors (TFs) influencing ovarian cancer progression. Furthermore, by integrating clinical factors from a large cohort of bulk RNA sequencing data, we have established a novel prognostic model to investigate the impact of the tumor immune microenvironment on ovarian cancer patients. Furthermore, we have investigated the condition of immunological exhaustion.
RESULTS: Our study identified a distinct and highly proliferative subgroup of malignant epithelial cells, known as C2 TOP2A+ TCs. This subgroup primarily consisted of patients who hadn't received neoadjuvant chemotherapy. Ovarian cancer patients with elevated TOP2A expression exhibited heightened sensitivity to neoadjuvant chemotherapy (NACT). Moreover, the transcription factor MYBL2 in this subgroup played a critical role in ovarian cancer development. Additionally, we developed an independent prognostic indicator, the TOP2A TCs Risk Score (TTRS), which revealed a correlation between the High TTRS Group and unfavorable outcomes. Furthermore, immune infiltration and drug sensitivity analyses demonstrated increased responsiveness to Paclitaxel, Cisplatin, and Gemcitabine in the Low TTRS Group.
CONCLUSION: This research deepens our understanding of malignant epithelial cells in ovarian cancer and enhances our knowledge of the ovarian cancer immune microenvironment and immune exhaustion. We have revealed the heightened susceptibility of the C2 TOP2A+ TCs subgroup to neoadjuvant chemotherapy and emphasized the role of MYBL2 within the C2 subgroup in promoting the occurrence and progression of ovarian cancer. These insights provide valuable guidance for the management of ovarian cancer treatment.
Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.
The invention relates to isolated clones of DNA from Plasmodium falciparum that encode a histidine-rich protein from that organism. The PfHRPII protein is expressed in P. falciparum-infected erythrocytes. The cloned gene segment includes an intron-exon boundary near the amino-terminus of the coding sequence. The PfHRPII protein has a Mr of 60-80 kDa as determined by SDS-PAGE. This is substantially higher than the molecular weight of about 35 kDa as estimated from the predicted amino acid sequence of PfHRPII. The PfHRPII amino acid sequence includes a hydrophobic leader sequence, consistent with secretion of PfHRPII observed in vivo and in vivo. The amino acid sequence of PfHRPII is also characterized by a number of tandem repeats having a high content of histidine, alanine and aspartic acid.
PURPOSE:To provide a cosmetic having freely adjustable feeling to the skin, giving gradually changing feeling to the skin, and applicable uniformly, by compounding spherical soft resin capsules collapsible by compression and containing a component selected from skin emollient component, perfumery and drug component. CONSTITUTION:The objective cosmetic contains spherical soft resin capsules collapsible by compression and containing a component selected from a skin emollient (e.g. higher fatty acid, higher alcohol, wax, etc.), perfumery, and a drug component (e.g. vitamin). The capsule is made of a homopolymer or copolymer of (meth)acrylic acid (ester), vinyl acetate, vinyl chloride, ethylene, etc., and has a particle diameter of 1-100mum and a compressive (breakage) strength of 5- 50kg/cm<2>. It can be collapsed easily by the pressure with fingers, and turns from the dry feeling to the moistened feeling when the capsule contains a skin emollient. The cosmetic is especially suitable for make-up.
Colon or rectal carcinoma that has spread to the liver is considered to be metastatic and is a Stage IV cancer. If the metastasized tumor is unresectable, the only current treatment is chemotherapy. Transarterial Chemoembolization (TACE) is considered as a palliative treatment in advanced metastatic colorectal carcinoma (mCRC), with the potential of local tumor control. TACE has evolved in the past 8 years to include drug-delivery devices that can target and deliver drugs from small microparticles (DEB-TACE). Superselective DEB-TACE has the potential to penetrate deeper into the tumor's vasculature to reach peripheral growing points. Loading these microparticles with a cytotoxic drug may improve the level of local tumor control.

The MIRACLE III study is a controlled, pilot, single center (Italy) study on 18 subjects with pretreated non-resectable mCRC.
The present disclosure relates to a method that may include retrieving an individual profile for an individual and a sequence dataset associated with the individual profile. The method may include determining an ancestral composition of the sequence dataset. The ancestral composition includes one or more ancestral groups. The method may also include retrieving one or more group residual risk values corresponding to the one or more ancestral groups. Each group residual risk value may be specific to an ancestral group and determined based on a carrier frequency and a detection rate specific to the ancestral group. The method may also include assigning metadata to the individual profile. The metadata may include a personalized residual risk of the individual. The personalized residual risk may be determined based on the one or more group residual risk values.
Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.
PURPOSE:The titled activator, containing an amino acid or a salt thereof as an active constituent, and having high safety even on continuous use thereof for a long term. CONSTITUTION:An activator for the administration of insulin containing an amino acid of formula I (R<1> is H, nitro, OH or esterified and protected OH: -Y- is direct bond, lower alkylene, vinylene, -CH2-O- or -O-CH2-; R<2> is substituted or unsubstituted phenyl or naphthyl; R<2>-Y-CO is N-benzyloxycarbonyl- phenylalanyl) or a salt thereof, e.g. a compound of formula II, as an active constituent. The activator can be administered by the oral or parenteral route, e.g. the rectum. The use thereof with insulin exhibits the activating effect on the insulin and further inhibitory effect on the trypsin and/or chymotrypsin which are proteolytic enzymes capable of hydrolyzing the insulin.
The invention discloses a medicinal cushion with Chinese herbal medicines for a bathing towel. The invention has the aim of providing a bathing article with the functions of prevention and health care to skin for overcoming the defect of a background technology. The medicinal cushion with the Chinese herbal medicines for the bathing towel comprises moxa, roses, solanum vines, valerian, rhizoma nardostachyos, fructus kochiae, fructus cnidii, kuh-seng, lindera glauca leaves and the like. The traditional Chinese medicines are prepared into the medicinal cushion, and the medicinal cushion is added with a non-woven fabric and is fixed, sheared, sealed and packaged. When the medicinal cushion with the Chinese herbal medicines for the bathing towel is used, the medicinal cushion is placed into a purpose-made bathing and rubbing towel (a soft face) so as to soak the medicinal cushion, the skin is repeatedly rubbed and washed, and then the residual medicine is completely flushed by using purified water. Or, the medicinal cushion is directly placed into a bathtub for releasing the medicine effect of the medicinal cushion into water, then a whole body is soaked in the medicinal water for 10 minutes, and afterwards the residual medicine is completely flushed by using the purified water. The medicinal cushion with the Chinese herbal medicines for the bathing towel has a favorable improving function to mental and physical fatigue, dreaminess, insomnia, skin dryness, skin pruritus and hair wilt. The medicinal cushion with the Chinese herbal medicines for the bathing towel has the characteristics of low price and convenience in use.